Loading…
for educational and safety purposes
Fladrafinil and Modafinil both come up in the same conversations; they overlap on Wakefulness. Fladrafinil: Fladrafinil (CRL-40,941) is a synthetic wakefulness drug from the same French research programme of the 1970s and 1980s that produced modafinil and adrafinil; chemically it is adrafinil with a fluorine atom added to each of its two rings. Modafinil: Modafinil is a prescription wakefulness-promoting drug, approved in the United States in 1998 for excessive sleepiness caused by narcolepsy, obstructive sleep apnea, and shift work disorder.
Fladrafinil (CRL-40,941) is a synthetic wakefulness drug from the same French research programme of the 1970s and 1980s that produced modafinil and adrafinil; chemically it is adrafinil with a fluorine atom added to each of its two rings. It was never approved or marketed as a medicine anywhere, and it now circulates online as a research chemical and turns up in products sold as nootropic supplements. The body converts it into flmodafinil, which is what actually produces the effect; that conversion has been demonstrated directly in people, but almost nothing else about the drug has been tested in humans. There are no efficacy trials, no safety studies and no published measurement of what it binds to, so claims that it sharpens focus or that it is several times stronger than adrafinil rest on marketing and a 1984 patent rather than on evidence.
Modafinil is a prescription wakefulness-promoting drug, approved in the United States in 1998 for excessive sleepiness caused by narcolepsy, obstructive sleep apnea, and shift work disorder. It works mainly by blocking the dopamine transporter, the protein that clears dopamine out of the synapse; human brain imaging confirms it occupies roughly half of those transporters at ordinary doses, although it binds them far more weakly than classic stimulants do. The evidence that it reduces sleepiness in the three approved sleep disorders is strong and rests on large placebo-controlled trials, but the evidence that it improves thinking in healthy, well-rested people is much weaker; the best meta-analysis found only a small overall effect confined to one narrow memory task. It is a Schedule IV controlled substance in the United States, banned in competition by WADA, and carries warnings for rare but serious skin reactions and for making hormonal birth control less reliable.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
weakly inhibits reuptake
weak selective inhibitor
increases signaling
increases signaling
Fladrafinil is a hydroxamic acid that is hydrolysed in vivo to the corresponding amide, flmodafinil, which carries the pharmacological activity
Downstream mediator of behavioural effect, not a binding site.
Indirect. Apparent occupancy changes because synaptic dopamine rises, not because modafinil binds the receptor.
Indirect circuit activation.
Required downstream circuit for arousal.
inhibits
raises
Indirect circuit activation; not required for wake promotion.
No meaningful interaction demonstrated.
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.
easiest to source: Fladrafinil is currently listed by more trusted vendors (3), so it's the simpler one to get hold of. for effects and safety, read each full entry; this is educational, not medical advice.